Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference

Repligen (NASDAQ:RGEN) will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, MA.

Rhea-AI Summary

Repligen (NASDAQ:RGEN) will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. President and CEO Olivier Loeillot and CFO Jason Garland are scheduled for an analyst-led discussion on September 9 at 1:30 p.m. ET.

A live webcast and limited-time replay of the presentation will be available through Repligen’s Investor Relations website. The company develops and commercializes bioprocessing technologies for biopharmaceutical developers and CDMOs worldwide.

Argus Aug 26 session

-0.77% close to close Open Argus

Details

News Market Reaction – RGEN

On Aug 26, the day this news came out, RGEN closed 0.77% below the previous close.

Data tracked by StockTitan Argus for the Aug 26 session.

Key Figures

Conference edition: 21st annual Discussion date: September 9th Discussion time: 1:30 p.m. ET

Conference edition

21st annual

Wells Fargo Healthcare Conference

Discussion date

September 9th

Analyst-led conference discussion

Discussion time

1:30 p.m. ET

September 9th analyst-led discussion

Historical Context

5 past events · Latest: Jul 28

5 events

1. Jul 28

   Earnings and guidance

   24h Move

   +10.9%

   Q2 results and full-year guidance update accompanied by BioLife acquisition announcement

2. Jul 22

   Acquisition agreement

   24h Move

   +2.3%

   Cash-and-stock BioLife transaction expanded cell therapy capabilities and projected synergies

3. Jul 15

   Earnings scheduling

   24h Move

   +0.6%

   Company scheduled its Q2 results release and conference call for July 28

4. May 22

   Conference presentation

   24h Move

   +1.5%

   Repligen announced participation in the William Blair growth stock conference

5. May 20

   Sustainability report

   24h Move

   +3.0%

   Corporate sustainability report detailed renewable electricity and reduced water withdrawals

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

bioprocessing, cdmos, chromatography, process analytics

4 terms

bioprocessing technical

"focused on bioprocessing technology leadership"

Bioprocessing is the set of manufacturing steps that use living cells or biological ingredients to make medicines, vaccines, diagnostics, or other biological products. Think of it as an assembly line where living systems, rather than machines, create the final product; variations in scale, consistency and cost directly affect a product’s ability to reach patients and generate revenue. Investors watch bioprocessing for its impact on production risk, regulatory approval and profit margins.

cdmos technical

"contract development and manufacturing organizations (CDMOs) worldwide"

Contract Development and Manufacturing Organizations (CDMOs) are independent companies that help drug and biologic developers by designing, testing, scaling up and producing medicines on a contract basis — think of them as a hired factory and research partner that turns a medical idea into a manufacturable product. They matter to investors because they provide steady, service-based revenue, spread development and production risk for drug makers, and their capacity, quality and pricing can directly affect the speed and cost of getting medicines to market.

chromatography technical

"Our focus areas are Filtration and Fluid Management, Chromatography"

Chromatography is a laboratory method for separating the parts of a mixture so each component can be identified and measured, like sorting colored marbles or filtering different dyes from a liquid. Investors care because it proves product purity, detects impurities or contaminants, and supports regulatory approvals and consistent manufacturing; failures or delays in these tests can affect costs, launch timing and liability risk.

process analytics technical

"Chromatography, Process Analytics and Proteins"

Process analytics is the use of data and statistical tools to map, measure and understand how a company’s operational workflows actually run—tracking steps, timing, bottlenecks and errors from logs, sensors or business software. Like a mechanic reading engine sensors to find where a car is losing power, it shows where processes waste time or cost money. Investors care because those insights reveal potential for efficiency gains, cost reduction and more reliable forecasting of future performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. Olivier Loeillot, President and Chief Executive Officer and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on September 9^th at 1:30 p.m. ET.

A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the Company see our website at www.repligen.com, and follow us on LinkedIn.

Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Repligen (NASDAQ:RGEN) present at the Wells Fargo 21st Annual Healthcare Conference?

Repligen is scheduled to present on September 9 at 1:30 p.m. ET. According to Repligen, President and CEO Olivier Loeillot and CFO Jason Garland will take part in an analyst-led discussion during the Boston-based conference.

How can investors access Repligen's webcast from the Wells Fargo Healthcare Conference 2026?

Investors can access a live webcast via Repligen’s Investor Relations website. According to Repligen, the conference presentation will also be available as a replay for a limited period following the event for those unable to attend live.

Who will represent Repligen (RGEN) at the Wells Fargo 21st Annual Healthcare Conference?

Repligen will be represented by Olivier Loeillot, President and CEO, and Jason Garland, CFO. According to Repligen, they will join an analyst-led discussion focused on the company and its bioprocessing technology business.

Where is the Wells Fargo 21st Annual Healthcare Conference featuring Repligen being held?

The conference is being held in Boston, Massachusetts. According to Repligen, its management will participate in an analyst-led discussion there, with a live webcast and replay available through the company’s Investor Relations website for remote viewers.

What does Repligen Corporation (RGEN) do in the life sciences and bioprocessing market?

Repligen develops and commercializes bioprocessing technologies and systems for biological drug manufacturing. According to Repligen, it serves biopharmaceutical developers and CDMOs with solutions in Filtration and Fluid Management, Chromatography, Process Analytics and Proteins worldwide.